Published on
June 23, 2026
- 13:15 GMT
Rubix LS Announces New Evidence-to-Product Initiatives in Collaboration with TheraSyn Bio
Rubix LS will lead new evidence assets in CKD, colorectal cancer, and postpartum risk conversion in collaboration with TheraSyn Bio. LAWRENCE, MA, UNITED STATES, June 23, 2026 /EINPresswire.com/ -- Rubix LS, a clinical research and evidence generation …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
